[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354377-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354377-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","homomultimeric-fap-inhibitor-based-radioligands-for-cancer-theranostics-design-principles-structure-function-relationships-and-preclinical-performance","Homomultimeric FAP Inhibitor-Based Radioligands for Cancer Theranostics - Design Principles, Structure-Function Relationships, and Preclinical Performance","","Fibroblast activation protein (FAP) is a promising target for cancer radiotheranostics because it is selectively overexpressed in cancer-associated fibroblasts (CAFs) within the tumor stroma. Affinity and selectivity describe how strongly FAP inhibitors bind FAP, while radiolabeled accumulation depends on tumor type. Monomeric FAP inhibitors face clinical limits from short retention and heterogeneous uptake. Homomultimeric FAPI ligands, using two or more identical FAP motifs, aim to increase binding avidity and extend tumor residence. This review tracks their molecular evolution and preclinical/early clinical performance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/homomultimeric-fap-inhibitor-based-radioligands-for-cancer-theranostics-design-principles-structure-function-relationships-and-preclinical-performance/354377/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/homomultimeric-fap-inhibitor-based-radioligands-for-cancer-theranostics-design-principles-structure-function-relationships-and-preclinical-performance/354377.png","ImageObject",300,407,{"name":42,"@type":43},"Kurz","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is FAP a target for cancer theranostics?","Question",{"text":63,"@type":64},"FAP is selectively overexpressed in cancer-associated fibroblasts within the tumor microenvironment, supporting tumor-directed radiopharmaceutical targeting.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What limitations affect monomeric FAP inhibitors in therapy?",{"text":68,"@type":64},"Monomeric radiolabeled FAPI agents show transient tumor retention and heterogeneous uptake across lesions with different stromal densities.",{"name":70,"@type":61,"acceptedAnswer":71},"How do homomultimeric FAPI ligands improve outcomes compared with monomers?",{"text":72,"@type":64},"By incorporating two or more identical FAP-targeting motifs, they enhance binding avidity and prolong tumor residence, which can improve tumor-to-background ratios and sustained uptake.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354377,1790915829,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":97,"preview_urls":146},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Review  \nHomomultimeric FAP Inhibitor-Based Radioligands for Cancer Theranostics: Design Principles, Structure–Function Relationships, and Preclinical Performance  \nZhiyang Wu 1,*, Eleni Gourni 2, Sanjana Ballal 3, Pieter Van der Veken 4 and Frank Roesch 5, *  \nAcademic Editor: Kazuma Ogawa  \nReceived: 21 April 2026  \nRevised: 23 May 2026  \nAccepted: 27 May 2026  \nPublished: 16 June 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 SCV Spezial-Chemikalien-Vertrieb GmbH, 10243 Berlin, Germany  \n2 Department of Nuclear Medicine, Inselspital, Bern University Hospital, CH-3010 Bern, Switzerland; [eleni.gourni@insel.ch](eleni.gourni@insel.ch)  \n3 Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi 110029, India; [mail.sanjanaballal87@gmail.com](mail.sanjanaballal87@gmail.com)  \n4 Laboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, University of Antwerp, 2610 Wilrijk, Belgium; [pieter.vanderveken@uantwerpen.be](pieter.vanderveken@uantwerpen.be)  \n5 Department of Chemistry–TRIGA Site, Johannes Gutenberg-University Mainz, 55128 Mainz, Germany  \n* Correspondence: zhiyang.wu@scv-company.com (Z.W.); [frank.roesch@uni-mainz.de](frank.roesch@uni-mainz.de) (F.R.)  \nAbstract  \nFibroblast activation protein (FAP) has emerged as a promising target for the development of cancer radiotheranostics due to its selective overexpression in cancer-associated fibroblasts (CAFs) within the tumor stroma. Affinity and selectivity refer to the binding affinities of FAP inhibitors toward FAP and related family members, whereas the accumulation of radiolabeled-FAP inhibitors varies by tumor type. Although monomeric FAP inhibitors (FAPIs) have shown extraordinary utility in diagnostic imaging, their clinical application in radiotherapy has been limited by short tumor retention times and heterogeneous uptake. To address these challenges, homomultimeric FAPI ligands—featuring two or more identical FAP-targeting motifs—have been developed with the aim of enhancing binding avidity and prolonging tumor residence. This review comprehensively examines the evolution of homomultimeric FAPI ligands, from molecular design and preclinical validation to early clinical implementation. We highlight how dimeric and higher-order multimeric constructs improve tumor retention and therapeutic efficacy compared to monomers, while also discussing the impact of linker chemistry, valency, and scaffold architecture on pharmacokinetics and targeting efficiency. Preclinical studies demonstrate that optimized dimersand trimers achieve superior tumor-to-background ratios and sustained tumor uptake, whereas excessive multimerization can lead to steric hindrance and reduced efficacy. Clinical data from pioneering studies using agents such as [177Lu]Lu-DOTAGA.(SA.FAPi) 2 and [177Lu]Lu-DOTAGA.Glu.(FAPi) 2 confirm prolonged tumor retention, encouraging therapeutic responses and a favorable safety profile in advanced cancers. However, translational challenges remain, including the need for better preclinical models that reflect stromal FAP heterogeneity, optimized radiometal–chelator pairs, and standardized dosing protocols for comparative clinical trials. Overall, homomultimeric FAPI ligands represent a significant advance in FAP-targeted theranostics, offering a robust platform for personalized cancer management.  \nKeywords: homomultimeric; FAPI ligands; theranostics; fibroblast activation protein (FAP); radioligand therapy (RLT); dimerization; multimerization  \n1. Introduction  \nFibroblast activation protein (FAP), a type II transmembrane serine protease, has received significant attention as a biomarker in oncology due to its selective overexpression in cancer-associated fibroblasts (CAFs) within the tumor microenvironment (TME) of over 90% of epithelial cancers [1–3] . FAP p","cbCainuViMEk2KxW","https://ap.wps.com/l/cbCainuViMEk2KxW","pdf",9463117,47,"English","# Introduction\n## Multimeric strategy for improved tumor retention\n# Homomultimeric FAPI ligands and design drivers\n## Linker chemistry, valency, and scaffold architecture\n## Preclinical performance and tumor-to-background ratios\n## Clinical implementation and translational challenges","[{\"question\":\"Why is FAP a target for cancer theranostics?\",\"answer\":\"FAP is selectively overexpressed in cancer-associated fibroblasts within the tumor microenvironment, supporting tumor-directed radiopharmaceutical targeting.\"},{\"question\":\"What limitations affect monomeric FAP inhibitors in therapy?\",\"answer\":\"Monomeric radiolabeled FAPI agents show transient tumor retention and heterogeneous uptake across lesions with different stromal densities.\"},{\"question\":\"How do homomultimeric FAPI ligands improve outcomes compared with monomers?\",\"answer\":\"By incorporating two or more identical FAP-targeting motifs, they enhance binding avidity and prolong tumor residence, which can improve tumor-to-background ratios and sustained uptake.\"}]","Homomultimeric FAP Inhibitor-Based Radioligands for Cancer Theranostics - Design Principles, Structure-Function Relationships, and Preclinical Performance | PDF",1790110365,118,[147,151,155,159,163],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a87d18b0d1d5a55aa67f6cd751b247b4.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ced7be643b17b3822beb60463a352b26.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73d37c5014b524308e8b9cf9dbb3ab8c.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69b277e65df849b89595c9de6b631b24.webp",980,1385,{"page_no":97,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b4452f8997c31affdfe913034a4a3377.webp",979,1384]